Yale University has received US Food and Drug Administration (FDA) authorisation for the SalivaDirect polymerase chain reaction (PCR) Covid-19 test to detect the SARS-CoV-2 virus in pooled samples.

Developed by the Yale School of Public Health, SalivaDirect is an open-source RT-qPCR test that uses saliva samples to detect the virus.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Laboratories designated by the Yale School of Public Health have been authorised by the FDA to use the test with pools of five saliva samples at a time for the detection of the SARS-CoV-2 virus.

With pooled testing, laboratories will be able to combine saliva samples obtained from up to five individuals in one tube and process the multiple samples as a single test.

If the pool tests negative, all individuals in the pool will be classified as negative for the virus and won’t require any further testing.

However, if a pool tests positive, the laboratories will perform additional testing to detect the positive individuals.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Yale School of Public Health research scientist and SalivaDirect principal investigator Anne Wyllie said: “Adopting frequent testing as a new public health habit will help keep us safe from infection and keep our schools, workplaces and businesses open.

“Sample pooling with SalivaDirect provides labs with an additional tool they can use to minimise testing materials, increase throughput and report faster results.”

This sample pooling process helps to maintain the clinical sensitivity that is associated with real-time reverse transcription PCR tests.

It also helps laboratories to process Covid-19 tests and provide results faster.

In August last year, SalivaDirect obtained emergency use authorisation from the FDA. It can be used on a routine basis to screen people without symptoms related to Covid-19 or for those who may have the disease.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact